CELUW Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Mai 2024 @ 22:00):

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases...

Stats
Tagesvolumen	49 216.00
Durchschnittsvolumen	0.00
Marktkapitalisierung	67.74M
EPS	$-0.000270 ( 2023-06-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-12	Lim Kok Thay	Buy	21 410 983	Class A Common Stock
2024-01-12	Lim Kok Thay	Buy	16 500 000	Warrants (Right to Buy)
2024-01-12	Lim Kok Thay	Buy	6 529 818	Warrants (Right to Buy)
2024-01-12	Lim Kok Thay	Buy	5 352 746	Warrants (Right to Buy)
2024-01-12	Lim Kok Thay	Sell	6 529 818	Warrants (Right to Buy)

INSIDER POWER
55.73
Last 92 transactions
Buy: 110 408 052 \| Sell: 53 673 583

Celularity Inc. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Celularity Inc. Finanzdaten

Annual	2022
Umsatz:	$17.98M
Bruttogewinn:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2022
Umsatz:	$17.98M
Bruttogewinn:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2021
Umsatz:	$21.34M
Bruttogewinn:	$11.68M (54.76 %)
EPS:	$-0.00100

FY	2020
Umsatz:	$14.28M
Bruttogewinn:	$9.35M (65.46 %)
EPS:	$-0.0000335

Financial Reports:

No articles found.

Celularity Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Celularity Inc.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company\'s lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn\'s disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.